論文 - 詳細
| RRC ID | 31869 |
|---|---|
| 著者 | Masuko K, Wakita D, Togashi Y, Kita T, Kitamura H, Nishimura T. |
| タイトル | Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy. |
| ジャーナル | Immunol Lett |
| Abstract |
To elucidate the immunologic mechanisms of artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP), which indicated a great vaccine efficacy in human cancers, we prepared ovalbumin (OVA)-H/K-HELP by conjugating killer and helper epitopes of OVA-model tumor antigen via a glycine-linker. Vaccination of C57BL/6 mice with OVA-H/K-HELP (30 amino acids) but not with short peptides mixture of class I-binding peptide (8 amino-acids) and class II-binding peptide (17 amino-acids) combined with adjuvant CpG-ODN (cytosine-phosphorothioate-guanine oligodeoxynucleotides), induced higher numbers of OVA-tetramer-positive CTL with concomitant activation of IFN-γ-producing CD4(+) Th1 cells. However, replacement of glycine-linker of OVA-H/K-HELP with other peptide-linker caused a significant decrease of vaccine efficacy of OVA-H/K-HELP. In combination with adjuvant CpG-ODN, OVA-H/KHELP exhibited greater vaccine efficacy compared with short peptides vaccine, in both preventive and therapeutic vaccine models against OVA-expressing EG-7 tumor. The elevated vaccine efficacy of OVAH/K-HELP might be derived from the following mechanisms: (i) selective presentation by only professional dendritic cells (DC) in vaccinated draining lymph node (dLN); (ii) a long-term sustained antigen presentation exerted by DC to stimulate both CTL and Th1 cells; (iii) formation of three cells interaction among DC, Th and CTL. In comparative study, H/K-HELP indicated stronger therapeutic vaccine efficacy compared with that of extended class I synthetic long peptide, indicating that both the length of peptide and the presence of Th epitope peptide were crucial aspects for preparing artificially synthesized H/K-HELP vaccine. |
| 巻・号 | 163(1) |
| ページ | 102-12 |
| 公開日 | 2015-1-1 |
| DOI | 10.1016/j.imlet.2014.11.016 |
| PII | S0165-2478(14)00295-8 |
| PMID | 25479286 |
| MeSH | Adjuvants, Immunologic / pharmacology* Animals Cancer Vaccines / chemistry Cancer Vaccines / immunology* Cell Line, Tumor Dendritic Cells / immunology Dendritic Cells / pathology Epitopes, T-Lymphocyte / chemistry Epitopes, T-Lymphocyte / immunology Epitopes, T-Lymphocyte / pharmacology* Humans Immunity, Cellular / drug effects Mice Neoplasms, Experimental / drug therapy* Neoplasms, Experimental / immunology Neoplasms, Experimental / pathology Oligodeoxyribonucleotides / pharmacology* Peptides / chemical synthesis Peptides / chemistry Peptides / immunology Peptides / pharmacology* Th1 Cells / immunology Th1 Cells / pathology |
| IF | 3.276 |
| 引用数 | 5 |
| WOS 分野 | IMMUNOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 12 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 3.0 |
| リソース情報 | |
| 実験動物マウス | RBRC00144 |